{{medical}}
{{noteTA|G1 = ME|G2=LS}}
{{Infobox medical condition (new)
| name            = 急性骨髓性白血病
| synonyms        =
| field           = [[血液學|血液學]]、[[肿瘤学|肿瘤学]]
| image           = Auer_rods.PNG
| caption     = 骨髓穿刺的檢體顯示急性骨髓性白血病，箭頭所指為{{tsl|en|Auer rod|棒狀體}}。
| symptoms     = 倦怠、[[呼吸困難|呼吸困難]]、容易瘀青或出血、[[感染|感染]]風險增加<ref name=NCI2017Pt/>
| complications   = 
| onset           = 所有年齡，最常發生在65–75歲<ref name=SEER2017/>
| duration        = 
| types           = 
| causes          = 
| risks           = [[吸菸|吸菸]]、[[化學治療|化學治療]]或[[放射治療|放射治療]]、[[骨髓增生异常综合征|骨髓增生异常综合征]]、[[苯|苯]]<ref name=NCI2017Pt/>
| diagnosis       = [[骨髓穿刺|骨髓穿刺]]、[[血液检查|血液检查]]<ref name=NEJM2015/>
| differential    = 
| prevention      = 
| treatment       = [[化學治療|化學治療]]、[[放射治療|放射治療]]、[[骨髓移植|骨髓移植]]<ref name=NCI2017Pt/><ref name=NEJM2015/>
| medication      = 
| prognosis       = [[五年存活率|五年存活率]]約27%（美國）<ref name=SEER2017/>
| frequency       = 百萬分之一（2015）<ref name=GBD2015Pre/>
| deaths          = 每年約15萬人（2015）<ref name=GBD2015De/>
}}
<!-- Definition and symptoms -->
'''急性骨髓性白血病'''（acute myeloid leukemia，AML）又稱'''急性髓系白血病'''，是一種[[髓細胞|骨髓性]][[血细胞|血液細胞]]過度增生造成的[[癌症|癌症]]，特色為大量不正常的細胞在[[骨髓|骨髓]]和[[血液|血液]]中快速生長，而干擾[[造血作用|造血作用]]<ref name=NCI2017Pt/>。症狀可能包括疲倦、[[呼吸困難|呼吸困難]]、容易瘀青和流血、[[感染|感染]]風險增加等<ref name=NCI2017Pt>{{cite web|title=Adult Acute Myeloid Leukemia Treatment|url=https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq#section/all|website=National Cancer Institute|accessdate=19 December 2017|language=en|date=6 March 2017|archive-date=2018-10-23|archive-url=https://web.archive.org/web/20181023012318/https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq#section/all|dead-url=no}}</ref>。癌細胞有時也會散佈到腦、皮膚、牙齦等處<ref name=NCI2017Pt/>。作為一種[[急性白血病|急性白血病]]，急性骨髓性白血病進展迅速，沒有治療的話通常會在數週至數個月內喪命<ref name=NCI2017Pt/><ref>{{cite book|last1=Marino|first1=Bradley S.|last2=Fine|first2=Katie S.|title=Blueprints Pediatrics|date=2013|publisher=Lippincott Williams & Wilkins|isbn=9781451116045|page=205|url=https://books.google.ca/books?id=OsmaeXtE7sQC&pg=PA205|language=en|access-date=2020-07-20|archive-date=2021-03-21|archive-url=https://web.archive.org/web/20210321150248/https://books.google.ca/books?id=OsmaeXtE7sQC&pg=PA205|dead-url=no}}</ref>。

<!-- Cause and diagnosis -->
急性骨髓性白血病的[[風險因子|風險因子]]有[[吸煙|吸煙]]、曾接受過[[化學治療|化學治療]]或[[放射治療|放射治療]]、患有[[骨髓增生异常综合征|骨髓增生异常综合征]]（MDS）和接觸特定的化學物質（如[[苯|苯]]）<ref name=NCI2017Pt/>。致病的機轉為正常的骨髓被白血病細胞取代，造成[[贫血|紅血球]]、{{tsl|en|thrombocytopenia|血小板減少症|血小板}}和正常的[[白细胞减少症|白血球]]減少<ref name=NCI2017Pt/>。診斷需藉助[[骨髓檢查|骨髓檢查]]與特定的[[血液检查|血液检查]]<ref name=NEJM2015/>。不同亞型的治療和預後則有很大的差異<ref name=NCI2017Pt/>。

<!-- Treatment -->
急性骨髓性白血病通常會先以[[化學療法|化學療法]]治療，以期能使疾病{{tsl|en|remission (medicine)|緩解 (醫學)|緩解}}<ref name=NCI2017Pt/>，患者在疾病緩解後可能會接受進一步的化學治療、放射治療或[[骨髓移植|骨髓移植]]<ref name=NCI2017Pt/><ref name=NEJM2015/>。若癌細胞有特定的[[突变|基因突變]]則會影響患者可能的存活時間和治療策略<ref name=NEJM2015/>

<!-- Epidemiology and prognosis -->
2015年，全球約有一百萬人罹患急性骨髓性白血病，並有147,000人因此死亡<ref name=GBD2015Pre>{{cite journal|last1=GBD 2015 Disease and Injury Incidence and Prevalence|first1=Collaborators.|title=Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015.|journal=Lancet|date=8 October 2016|volume=388|issue=10053|pages=1545–1602|pmid=27733282|doi=10.1016/S0140-6736(16)31678-6|pmc=5055577}}</ref><ref name=GBD2015De>{{cite journal|last1=GBD 2015 Mortality and Causes of Death|first1=Collaborators.|title=Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015.|journal=Lancet|date=8 October 2016|volume=388|issue=10053|pages=1459–1544|pmid=27733281|doi=10.1016/S0140-6736(16)31012-1|pmc=5388903}}</ref>。此病最常出現在老年人<ref name=SEER2017>{{cite web|title=Acute Myeloid Leukemia – Cancer Stat Facts|url=https://seer.cancer.gov/statfacts/html/amyl.html|website=NCI|accessdate=10 May 2017|language=en|archive-date=2017-07-28|archive-url=https://web.archive.org/web/20170728021217/https://seer.cancer.gov/statfacts/html/amyl.html|dead-url=no}}</ref>，且男性較女性多<ref name=SEER2017/>。60歲以下的五年生存率約35%，60歲以上的五年生存率約為10%<ref name=NEJM2015/>。接受化療的老年患者的[[中位生存期|中位生存期]]為6.1個月，而未接受化療的患者的中位生存期為1.7個月<ref name=NEJM2015>{{cite journal|last1=Döhner|first1=H|last2=Weisdorf|first2=DJ|last3=Bloomfield|first3=CD|title=Acute Myeloid Leukemia.|journal=The New England Journal of Medicine|date=17 September 2015|volume=373|issue=12|pages=1136–52|pmid=26376137|doi=10.1056/NEJMra1406184|url=https://semanticscholar.org/paper/ad0bc28b56dd47cb9c7aca6ad6611b90953cddbc}}</ref>。急性骨髓性白血病大約佔美國癌症死亡數的1.8%<ref name=SEER2017/>。
{{TOC limit|3}}

==症狀==
[[Image:AMLCase-66.jpg|thumb]]
急性骨髓性白血病的徵象和症候多半源自於白血病細胞取代了正常的血液細胞。缺乏正常的白血球將造成患者容易受到感染，雖然白血病細胞本身也是來自白血球的前驅細胞，但它們沒有對抗感染的能力<ref name="symptoms">{{cite book |last = Hoffman |first = Ronald |title= Hematology: Basic Principles and Practice |year= 2005 |publisher= {{tsl|en|Churchill Livingstone||Elsevier Churchill Livingstone}} |location= [[圣路易斯_(密苏里州)|St. Louis, Mo.]] |edition = 4th |pages = 1074–75 |isbn= 978-0-443-06629-0 }}</ref>；紅血球減少（[[貧血|貧血]]）將造成身體疲勞、膚色蒼白和呼吸困難；[[血小板|血小板]]低下則會使患者容易瘀傷或因微小的創傷而血流不止。

急性骨髓性白血病早期的表現通常很隱晦且不具特異性，症狀可能和[[流行性感冒|流行性感冒]]或其他常見的疾病類似。常見的全身性症狀包括[[發燒|發燒]]、[[疲勞|疲勞]]、[[體重下降|體重下降]]、[[食慾不振|食慾不振]]、[[呼吸困難|呼吸困難]]、貧血、容易瘀青或流血、[[瘀點|瘀點]]（皮下出血所形成的平整小紅點，約如針頭大小）、骨痛或關節痛、持續或經常[[感染|感染]]<ref name = "symptoms"/>。

{{tsl|en|Splenomegaly|脾腫大}}也可能發生，但通常較輕微且無症狀；和[[急性淋巴性白血病|急性淋巴性白血病]]相反，{{tsl|en|lymphadenopathy|淋巴腫大}}在急性骨髓性白血病中很罕見。約10%的患者會以{{tsl|en|leukemia cutis|皮膚白血病}}的形式呈現。很少數的患者會出現{{tsl|en|Sweet's syndrome|史維特症候群}}，這是一種會造成皮膚發炎的[[腫瘤伴隨症候群|腫瘤伴隨症候群]]<ref name = "symptoms"/>。

有些患者會因為白血病細胞浸潤而造成牙齦腫大。少數患者第一個發現的症狀可能會是一個白血病細胞組成的腫塊，稱之為{{tsl|en|chloroma|綠色瘤}}。有時患者可能沒有任何症狀，但因接受常規[[血液检查|血液检查]]而意外發現白血病<ref>{{cite book |last = Abeloff |first = Martin |title= Clinical Oncology |year= 2004 |publisher= {{tsl|en|Churchill Livingstone||Elsevier Churchill Livingstone}} |location= [[圣路易斯_(密苏里州)|St. Louis, Mo.]] |edition = 3rd |isbn= 978-0-443-06629-0 |page = 2834 }}</ref>。

==風險因子==
目前已知可能造成急性骨髓性白血病的風險因子包括：其它血液疾病、暴露特定化學物質、游離輻射和基因。

===其它血液疾病===
一些可能演變為急性骨髓性白血病的血液疾病被稱為「前白血病」，例如[[骨髓增生异常综合征|骨髓增生异常综合征]]（MDS）或[[骨髓增殖性疾病|骨髓增殖性疾病]]（MPN）都屬此類，該疾病演變為急性骨髓性白血病的風險取決於該疾病本身的亞型<ref>{{cite journal |vauthors=Sanz GF, Sanz MA, Vallespí T, Cañizo MC, Torrabadella M, García S, Irriguible D, San Miguel JF | title = Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients | journal = Blood | volume = 74 | issue = 1 | pages = 395–408 | year = 1989 | pmid = 2752119 | doi = 10.1182/blood.V74.1.395.395 }}</ref>。無症狀的{{tsl|en|clonal hematopoiesis|複製性造血作用}}也會增加急性骨髓性白血病的風險，發生率約為每年0.5–1.0%<ref>{{Cite journal|last=Jaiswal|first=Siddhartha|last2=Fontanillas|first2=Pierre|last3=Flannick|first3=Jason|last4=Manning|first4=Alisa|last5=Grauman|first5=Peter V.|last6=Mar|first6=Brenton G.|last7=Lindsley|first7=R. Coleman|last8=Mermel|first8=Craig H.|last9=Burtt|first9=Noel|date=25 December 2014|title=Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes|journal=New England Journal of Medicine|volume=371|issue=26|pages=2488–2498|doi=10.1056/NEJMoa1408617|issn=0028-4793|pmc=4306669|pmid=25426837|url=http://lup.lub.lu.se/record/4815904|access-date=2020-07-20|archive-date=2021-08-27|archive-url=https://web.archive.org/web/20210827204534/https://lup.lub.lu.se/search/publication/4815904|dead-url=no}}</ref>。

===化學物質暴露===
接受抗癌[[化学疗法|化療]]藥品（尤其是[[烷化劑|烷化劑]]）會增加之後罹患急性骨髓性白血病的風險，此風險在接受治療後三至五年最高<ref>{{cite journal |vauthors=Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Golomb HM, Rowley JD | title = Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7 | journal = J Clin Oncol | volume = 4 | issue = 3 | pages = 325–45 | year = 1986 | pmid = 3950675 | doi = 10.1200/JCO.1986.4.3.325 }}</ref>；其他化療藥品如[[鬼臼毒素|鬼臼毒素]]（epipodophyllotoxins）和[[蒽环类药物|蒽环类药物]]（anthracycline）則特別和帶有特定染色體異常的白血病有關<ref>{{cite journal |vauthors=Thirman MJ, Gill HJ, Burnett RC, Mbangkollo D, McCabe NR, Kobayashi H, Ziemin-van der Poel S, Kaneko Y, Morgan R, Sandberg AA | title = Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations | journal = N Engl J Med | volume = 329 | issue = 13 | pages = 909–14 | year = 1993 | pmid = 8361504 | doi = 10.1056/NEJM199309233291302 }}</ref>。

[[苯|苯]]和其他芳香類[[溶劑|溶劑]]的職業暴露是否會造成白血病一直有爭議，苯和其衍生物在體外實驗中是已知的[[致癌物質|致癌物質]]，雖然一些研究認為長期暴露於這些化學物質會增加急性骨髓性白血病的風險<ref>{{cite journal |vauthors=Austin H, Delzell E, Cole P | title = Benzene and leukemia. A review of the literature and a risk assessment | journal = Am J Epidemiol | volume = 127 | issue = 3 | pages = 419–39 | year = 1988 | pmid = 3277397 | doi = 10.1093/oxfordjournals.aje.a114820 }}</ref>，但一些研究者認為這些暴露對風險的影響十分輕微<ref>Linet, MS. The Leukemias: Epidemiologic Aspects. [[牛津大學出版社|Oxford University Press]], New York 1985.</ref>。

===輻射暴露===
暴露於大量的[[游離輻射|游離輻射]]會增加急性骨髓性白血病的風險。廣島和長崎[[被爆者|原子彈攻擊的倖存者]]罹患急性骨髓性白血病的比率較高<ref>{{cite journal |vauthors=Bizzozero OJ, Johnson KG, Ciocco A | title = Radiation-related leukemia in Hiroshima and Nagasaki, 1946–1964. I. Distribution, incidence and appearance time | journal = N Engl J Med | volume = 274 | issue = 20 | pages = 1095–101 | year = 1966 | pmid = 5932020 | doi = 10.1056/NEJM196605192742001 }}</ref>；同樣地，大量暴露於[[X射線|X射線]]的[[影像诊断学|放射師]]在實施現代的輻射安全措施之前也有較高的罹病率<ref>{{cite journal | vauthors = Yoshinaga S, Mabuchi K, Sigurdson AJ, Doody MM, Ron E | title = Cancer risks among radiologists and radiologic technologists: review of epidemiologic studies | journal = Radiology | volume = 233 | issue = 2 | pages = 313–21 | year = 2004 | pmid = 15375227 | doi = 10.1148/radiol.2332031119 | url = https://semanticscholar.org/paper/d9e461af06bcb072bb4e525ba9e00bd0f332487c | access-date = 2020-07-20 | archive-date = 2020-12-24 | archive-url = https://web.archive.org/web/20201224121229/https://www.semanticscholar.org/paper/Cancer-risks-among-radiologists-and-radiologic-of-Yoshinaga-Mabuchi/d9e461af06bcb072bb4e525ba9e00bd0f332487c | dead-url = no }}</ref>。接受游離輻射治療的[[前列腺癌|前列腺癌]]、[[非霍奇金氏淋巴瘤|非霍奇金氏淋巴瘤]]、[[肺癌|肺癌]]和[[乳癌|乳癌]]患者罹患急性骨髓性白血病的風險較高，但這樣的風險在接受治療12年後會降低至與一般人無異<ref>{{Cite journal|title = Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation|journal = Leukemia|volume = 30|issue = 2|pages = 285–294|doi = 10.1038/leu.2015.258|pmid = 26460209|first = T|last = Radivoyevitch|first2 = R K|last2 = Sachs|first3 = R P|last3 = Gale|first4 = R J|last4 = Molenaar|first5 = D J|last5 = Brenner|first6 = B T|last6 = Hill|first7 = M E|last7 = Kalaycio|first8 = H E|last8 = Carraway|first9 = S|last9 = Mukherjee|year = 2016}}</ref>。

===遺傳===
有些急性骨髓性白血病似乎也和基因遺傳有關，過去曾有案例指出家族中的成員以高於尋常的比率發生急性骨髓性白血病<ref>{{cite book|vauthors=Taylor GM, Birch JM|chapter=The hereditary basis of human leukemia|veditors=Henderson ES, Lister TA, Greaves MF|title=Leukemia|edition=6th|location=Philadelphia|publisher=WB Saunders|year=1996|isbn=978-0-7216-5381-5|page=[https://archive.org/details/leukemia0000unse_y4y5/page/210 210]|chapter-url=https://archive.org/details/leukemia0000unse_y4y5|url=https://archive.org/details/leukemia0000unse_y4y5/page/210}}</ref><ref>{{cite journal |vauthors=Horwitz M, Goode EL, Jarvik GP | title = Anticipation in familial leukemia |url=https://archive.org/details/sim_american-journal-of-human-genetics_1996-11_59_5/page/990 | journal = Am. J. Hum. Genet. | volume = 59 | issue = 5 | pages = 990–8 | year = 1996 | pmid = 8900225 | pmc = 1914843 }}</ref><ref>{{cite journal | author = Crittenden LB | title = An interpretation of familial aggregation based on multiple genetic and environmental factors | journal = Ann. N. Y. Acad. Sci. | volume = 91 | issue = 3 | pages = 769–80 | year = 1961 | pmid = 13696504 | doi = 10.1111/j.1749-6632.1961.tb31106.x | bibcode = 1961NYASA..91..769C }}</ref><ref>{{cite journal | author = Horwitz M | title = The genetics of familial leukemia | journal = Leukemia | volume = 11 | issue = 8 | pages = 1347–59 | year = 1997 | pmid = 9264391 | doi = 10.1038/sj.leu.2400707 }}</ref>。一些[[先天性障碍|先天性障碍]]可能會增加白血病的風險，其中最常見的是[[唐氏综合征|唐氏症]]，唐氏症患者得到急性骨髓性白血病的風險約為常人的10至18倍<ref>{{cite journal |vauthors=Evans DI, Steward JK | title = Down's syndrome and leukaemia | journal = Lancet | volume = 2 | issue = 7790 | pages = 1322 | year = 1972 | pmid = 4117858 | doi = 10.1016/S0140-6736(72)92704-3 }}</ref>。此外，''{{tsl|en|GATA2|GATA2基因}}''基因的兩個對偶基因中的其中一個若發生[[突变|不活化突變]]（例如發生{{tsl|en|haploinsufficiency|單套缺失}}），該基因的產物GATA2[[轉錄因子|轉錄因子]]將會減少，造成一種罕見的[[显性|體染色體顯性]][[遺傳疾病|遺傳疾病]]——{{tsl|en|GATA2 deficiency|GATA2缺乏症}}，這個疾病有各式各樣的表現，罹患急性骨髓性白血病的機率大幅增加便是其一<ref name="pmid28179280">{{cite journal |vauthors=Crispino JD, Horwitz MS |title=GATA factor mutations in hematologic disease |journal=Blood |volume=129 |issue=15 |pages=2103–2110 |date=April 2017 |pmid=28179280 |pmc=5391620 |doi=10.1182/blood-2016-09-687889}}</ref><ref name="pmid28643018">{{cite journal | vauthors = Hirabayashi S, Wlodarski MW, Kozyra E, Niemeyer CM | title = Heterogeneity of GATA2-related myeloid neoplasms | journal = International Journal of Hematology | volume = 106 | issue = 2 | pages = 175–182 | date = August 2017 | pmid = 28643018 | doi = 10.1007/s12185-017-2285-2 | url = }}</ref>；在成人和孩童中，容易造成急性骨髓性白血病的基因異常往往不同<ref>{{cite journal |last1=Bolouri|first1=Hamid|title=The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions|journal=[[自然-医学|Nature Medicine]]|volume= 24|issue= 1|pages= 103–112|doi=10.1038/nm.4439|pmid=29227476|pmc=5907936|year=2018}}</ref>，但GATA2缺乏症導致的急性骨髓性白血病可能在孩童或成人時發生<ref name="pmid28643018"/>。

==診斷==
[[Image:Myeloblast_with_Auer_rod_smear_2010-01-27.JPG|thumb]]
診斷急性骨髓性白血病的第一個線索通常是不正常的[[全血球計數|全血球計數]]，雖然白血病常會有不正常的{{tsl|en|leukocytosis|白血球增多症|白血球增多}}，且有時確實能在周邊血見到白血病細胞，但急性骨髓性白血病也可能只出現[[血小板|血小板]]、[[紅血球|紅血球]]或[[白细胞减少症|白血球減少]]中的其中一個<ref>Abeloff, Martin et al. (2004), p. 2834.</ref>。雖然當血液中含有白血病細胞時，{{tsl|en|Blood film|周邊血液抹片}}能做出初步的診斷，但白血病的確診仍須靠[[骨髓檢查|骨髓抽吸或切片檢查]]，後者同時能排除[[惡性貧血|惡性貧血]]（維生素B12缺乏症）、[[葉酸缺乏症|葉酸缺乏症]]和{{tsl|en|copper deficiency|銅缺乏症}}<ref>{{Cite journal|last=Dokal|first=I. S.|last2=Cox|first2=T. M.|last3=Galton|first3=D. A.|date=12 May 1990|title=Vitamin B-12 and folate deficiency presenting as leukaemia|journal=BMJ (Clinical Research Ed.)|volume=300|issue=6734|pages=1263–1264|issn=0959-8138|pmc=1662842|pmid=2354298|doi=10.1136/bmj.300.6734.1263}}</ref><ref>{{Cite journal|last=Aitelli|first=Cristi|last2=Wasson|first2=Lori|last3=Page|first3=Ray|date=1 March 2004|title=Pernicious anemia: presentations mimicking acute leukemia|url=https://archive.org/details/sim_southern-medical-journal_2004-03_97_3/page/295|journal=Southern Medical Journal|volume=97|issue=3|pages=295–297|doi=10.1097/01.SMJ.0000082003.98003.88|issn=0038-4348|pmid=15043340}}</ref><ref>{{Cite journal|last=Zuo|first=Zhuang|last2=Polski|first2=Jacek M.|last3=Kasyan|first3=Armen|last4=Medeiros|first4=L. Jeffrey|date=1 September 2010|title=Acute erythroid leukemia|journal=Archives of Pathology & Laboratory Medicine|volume=134|issue=9|pages=1261–1270|doi=10.1043/2009-0350-RA.1|pmid=20807044|url=http://www.archivesofpathology.org/doi/10.1043/2009-0350-RA.1?url_ver=Z39.88-2003|doi-broken-date=2020-03-07|access-date=2020-07-20|archive-date=2020-07-26|archive-url=https://web.archive.org/web/20200726005304/https://www.archivesofpathology.org/doi/10.1043/2009-0350-RA.1?url_ver=Z39.88-2003|dead-url=yes}}</ref><ref>{{Cite journal|last=Barzi|first=Afsaneh|last2=Sekeres|first2=Mikkael A.|date=1 January 2010|title=Myelodysplastic syndromes: a practical approach to diagnosis and treatment|journal=Cleveland Clinic Journal of Medicine|volume=77|issue=1|pages=37–44|doi=10.3949/ccjm.77a.09069|pmid=20048028|url=https://semanticscholar.org/paper/eb78ec714f89e36906977b8e499982aaa7aa1456}}</ref>。

骨髓或周邊血液檢體將會用[[顯微鏡學|光學顯微鏡]]和[[流式細胞儀|流式細胞儀]]檢查，以確認白血病的診斷、區分是否可能為其他種白血病（如[[急性淋巴性白血病|急性淋巴性白血病]]）、並鑑別急性骨髓性白血病的亞型。此外，透過[[细胞遗传学|細胞基因分析]]和[[熒光原位雜交|熒光原位雜交]]也能檢查白血病細胞是否有[[染色体畸变|染色體異常]]；基因檢驗則用來確認白血病細胞是否帶有特定的基因突變，例如''{{tsl|en|FLT3||FLT3}}''、{{tsl|en|nucleophosmin|核仁磷酸基因|''NPM''}}和''{{tsl|en|CD117||KIT}}''，這些基因突變將影響疾病的預後和後續治療策略<ref>{{cite journal |vauthors=Baldus CD, Mrózek K, Marcucci G, Bloomfield CD | title = Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review | journal = Br. J. Haematol. | volume = 137 | issue = 5 | pages = 387–400 | date = June 2007 | pmid = 17488484 | doi = 10.1111/j.1365-2141.2007.06566.x | url = }}</ref>。

周邊血和骨髓的細胞化學染色在鑑別急性淋巴性白血病、急性骨髓性白血病及其亞型上很有用。使用非特異性彈性酶與[[髓過氧化物酶|髓過氧化物酶]]或蘇丹黑的雙重染色多半就能提供足夠的資訊，髓過氧化物酶或蘇丹黑能區分淋巴性和骨髓性的白血病，非特異性彈性酶則能染出急性骨髓性白血病細胞中的單核球內容物，辨識出分化不良的單核球母細胞白血病，進而與急性淋巴性白血病做區別<ref name=Vardiman>{{cite journal |vauthors=Vardiman JW, Harris NL, Brunning RD | title = The World Health Organization (WHO) classification of the myeloid neoplasms | journal = Blood | volume = 100 | issue = 7 | pages = 2292–302 | year = 2002 | pmid = 12239137 | doi = 10.1182/blood-2002-04-1199 | url = https://semanticscholar.org/paper/374f0337573868aa389106491a3d184986abe904 }}</ref>。

急性骨髓性白血病的診斷和分類十分困難，須由合格的{{tsl|en|hematopathologist|血液病理學家}}或[[血液學|血液專科醫師]]進行。在較單純的案例中，特定的形態學特徵（如出現{{tsl|en|Auer rod|棒狀體}}）或流式細胞儀結果能讓醫師辨識出急性骨髓性白血病，但若沒有這些特徵，診斷將會變得困難<ref>Abeloff, Martin et al. (2004), p. 2835.</ref>。

急性骨髓性白血病最常見的兩種分類架構分別為較舊的[[FAB分型|FAB分型]]系統和較新的[[世界衛生組織|世界衛生組織]]（WHO）系統。根據使用最廣泛的WHO條件，急性骨髓性白血病的診斷必須在骨髓或血液中看到20%以上的白血病{{tsl|en|myeloblast|骨髓母細胞}}，但若為預後最好的三種基因變異型（t(8;21)、inv(16)和t(15;17)）則不需考量骨髓母細胞的比例，單用基因即可診斷<ref>{{cite journal |vauthors=Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD | title = The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997 |url=https://archive.org/details/sim_annals-of-oncology_1999-12_10_12/page/1419 | journal = Ann Oncol | volume = 10 | issue = 12 | pages = 1419–32 | year = 1999 | pmid = 10643532 | doi = 10.1023/A:1008375931236 }}</ref><ref>{{cite web|last1=Foucar|first1=Kathryn|title=Bone Marrow Pathology|edition=3rd|url=http://www.ascp.org/PDF/Books/Chapter-18.pdf|archive-url=https://web.archive.org/web/20130319070612/http://www.ascp.org/PDF/Books/Chapter-18.pdf|url-status=dead|archive-date=19 March 2013|publisher=ASCP|accessdate=18 March 2016}}</ref>。FAB系統的條件則較為嚴格，要求骨髓或周邊血要有30%的骨髓母細胞<ref name=Amin2005>{{cite journal |vauthors=Amin HM, Yang Y, Shen Y, Estey EH, Giles FJ, Pierce SA, Kantarjian HM, O'Brien SM, Jilani I, Albitar M | title = Having a higher blast percentage in circulation than bone marrow: Clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias | journal = Leukemia | volume = 19 | issue = 9 | pages = 1567–1572 | year = 2005 | pmid = 16049515 | pmc = 使用| doi = 10.1038/sj.leu.2403876 }}</ref>。急性骨髓性白血病必須和「前白血病狀態」（例如[[骨髓增生異常症候群|骨髓增生異常症候群]]或[[骨髓增生性疾病|骨髓增生性疾病]]）小心區分，其治療方法並不相同。

由於{{tsl|en|acute promyelocytic leukemia|急性前骨髓細胞性白血病}}（APL）的療法獨特，且有最高的治癒率，因此快速的診斷出此種白血病亞型相當重要。周邊血或骨髓的螢光原位雜合反應可以偵測APL特有的[[染色體易位|染色體易位]][t(15;17)(q22;q12);]，因此常用做APL的診斷工具。此外，偵測出PML/RARA融合蛋白分子也相當重要，該蛋白為上述轉位造成的致癌產物<ref>{{cite journal |vauthors=Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H, Swirsky D, Wheatley K, Goldstone A, Burnett A, Solomon E | title = Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. M.R.C. Adult Leukaemia Working Party |url=https://archive.org/details/sim_british-journal-of-haematology_1996-09_94_3/page/557 | journal = Br J Haematol | volume = 94 | issue = 3 | pages = 557–73 | year = 1996 | pmid = 8790159 |doi=10.1046/j.1365-2141.1996.d01-1004.x| doi-broken-date = 2020-03-07 }}</ref>。

===WHO分類===
2008年版的WHO分類系統做了較大幅度的更動，嘗試讓急性骨髓性白血病的分類在臨床上更加實用，期望能提供更多疾病預後的資訊。每個WHO分類之下還有許多次分類，這些次分類可以提供醫師許多具有臨床重要性的資訊，也是{{tsl|en|hematopathologist|血液學|血液科醫師}}或[[肿瘤学|腫瘤科醫師]]用以溝通的工具。隨著基因定序技術和腫瘤標記的研究進展，WHO分類系統也在2016年做了更新。<ref name="ArberOrazi2016">{{cite journal|last1=Arber|first1=Daniel A.|last2=Orazi|first2=Attilio|last3=Hasserjian|first3=Robert|last4=Thiele|first4=Jürgen|last5=Borowitz|first5=Michael J.|last6=Le Beau|first6=Michelle M.|last7=Bloomfield|first7=Clara D.|last8=Cazzola|first8=Mario|last9=Vardiman|first9=James W.|title=The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia|journal=Blood|volume=127|issue=20|year=2016|pages=2391–2405|issn=0006-4971|doi=10.1182/blood-2016-03-643544}}</ref>

2016年版的WHO分類如下：

{| class="wikitable"
|-
! 名稱
! 描述
! {{tsl|en|ICD-O|國際腫瘤學疾病分類|ICD-O}}
|-
| '''復發性遺傳變異之急性骨髓性白血病'''
| 包含：

* [[8號染色體|8]]和[[21號染色體|21號染色體]]轉位之急性骨髓性白血病 – [t(8;21)(q22;q22);] {{tsl|en|RUNX1||RUNX1}}/{{tsl|en|RUNX1T1||RUNX1T1}}（ICD-O 9896/3）
* [[16號染色體|16號染色體]]倒位之急性骨髓性白血病 – [inv(16)(p13.1q22)]；或內部轉位 – [t(16;16)(p13.1;q22);] {{tsl|en|CBFB||CBFB}}/{{tsl|en|MYH11||MYH11}}（ICD-O 9871/3）
* [[15號染色體|15]]和[[17號染色體|17號染色體]]轉位之{{tsl|en|acute promyelocytic leukemia|急性前骨髓細胞性白血病}} – [t(15;17)(q22;q12);] [[视黄酸受体α|RARA]]/[[早幼粒细胞白血病蛋白|PML]]（ICD-O 9866/3）
* [[9號染色體|9]]和[[11號染色體|11號染色體]]轉位之急性骨髓性白血病 – [t(9;11)(p22;q23);] {{tsl|en|MLLT3||MLLT3}}/[[MLL_(基因)|MLL]]
* [[6號染色體|6]]和[[9號染色體|9號染色體]]轉位之急性骨髓性白血病 – [t(6;9)(p23;q34);] {{tsl|en|DEK (gene)||DEK}}/{{tsl|en|NUP214||NUP214}}
* [[3號染色體|3號染色體]]倒位之急性骨髓性白血病 – [inv(3)(q21q26.2)]；或內部轉位 – [t(3;3)(q21;q26.2);] {{tsl|en|RPN1||RPN1}}/{{tsl|en|EVI1||EVI1}}
* [[1號染色體|1]]和[[22號染色體|22號染色體]]轉位之急性巨核母細胞白血病 – [t(1;22)(p13;q13);] [[RBM15|RBM15]]/[[MKL1|MKL1]]
* {{tsl|en|NPM1||NPM1}}突變之急性骨髓性白血病
* {{tsl|en|CEBPA||CEBPA}}突變之急性骨髓性白血病

| 多個
|-
| '''骨髓增生不良相關轉變之急性骨髓性白血病'''
| 這個類別包含了過去被診斷為[[骨髓增生異常症候群|骨髓增生異常症候群]]（MDS）或[[骨髓增殖性疾病|骨髓增殖性疾病]]（MPD）但後來轉變為急性骨髓性白血病，或帶有此分類中所列細胞遺傳學特徵的急性骨髓性白血病（可能是過去有MDS或MPD但未被診斷出來，而細胞遺傳學特徵仍傾向患者過去曾有MPS或MPD）。此類急性骨髓性白血病多發生在老人，預後也較差。
* 複雜[[核型|核型]]之急性骨髓性白血病
* 不平衡之染色體異常
** [[7號染色體|7號染色體]]缺失之急性骨髓性白血病 – [del(7q);]
** [[5號染色體|5號染色體]]缺失之急性骨髓性白血病 – [del(5q);]
** [[17號染色體|17號染色體]]不平衡異常之急性骨髓性白血病 – [i(17q)/t(17p);]
** [[13號染色體|13號染色體]]缺失之急性骨髓性白血病 – [del(13q);]
** [[11號染色體|11號染色體]]缺失之急性骨髓性白血病 – [del(11q);]
** [[12號染色體|12號染色體]]不平衡異常之急性骨髓性白血病 – [del(12p)/t(12p);]
** [[9號染色體|9號染色體]]缺失之急性骨髓性白血病 – [del(9q);]
** [[X染色體|X染色體]]異常之急性骨髓性白血病 – [idic(X)(q13);]
* 平衡之染色體異常
** [[11號染色體|11]]和[[16號染色體|16號染色體]]轉位之急性骨髓性白血病 – [t(11;16)(q23;q13.3);]，和化學治療或游離輻射無關
** [[3號染色體|3]]和[[21號染色體|21號染色體]]轉位之急性骨髓性白血病 – [t(3;21)(q26.2;q22.1);]，和化學治療或游離輻射無關 
** [[1號染色體|1]]和[[3號染色體|3號染色體]]轉位之急性骨髓性白血病 – [t(1;3)(p36.3;q21.1);]
** [[2號染色體|2]]和[[11號染色體|11號染色體]]轉位之急性骨髓性白血病 – [t(2;11)(p21;q23);]，和化學治療或游離輻射無關 
** [[5號染色體|5]]和[[12號染色體|12號染色體]]轉位之急性骨髓性白血病 – [t(5;12)(q33;p12);]
** [[5號染色體|5]]和[[7號染色體|7號染色體]]轉位之急性骨髓性白血病 – [t(5;7)(q33;q11.2);]
** [[5號染色體|5]]和[[17號染色體|17號染色體]]轉位之急性骨髓性白血病 – [t(5;17)(q33;p13);]
** [[5號染色體|5]]和[[10號染色體|10號染色體]]轉位之急性骨髓性白血病 – [t(5;10)(q33;q21);]
** [[3號染色體|3]]和[[5號染色體|5號染色體]]轉位之急性骨髓性白血病 – [t(3;5)(q25;q34);]

| {{ICDO|9895|3}}
|-
| '''治療相關之骨髓瘤'''
| 此分類包括過去曾接受化學藥物治療或放射治療，並在之後罹患急性骨髓性白血病或骨髓增生不良症候群的患者，這些白血病可能帶有特定的染色體異常，預後通常較差。
| {{ICDO|9920|3}}
|-
| '''{{tsl|en|Myeloid sarcoma|骨髓性肉瘤}}'''
| 此分類包含骨髓性肉瘤（myeloid sarcoma）。
|
|-
| '''[[唐氏综合征|唐氏症]]相關之骨髓增生疾病'''
| 次分類包括了暫時性骨髓增生疾病（transient abnormal myelopoiesis）和唐氏症相關之骨髓性白血病（myeloid leukemia associated with Down syndrome）。
|
|-
| '''芽細胞胞漿性樹突狀細胞瘤'''
| 此分類包括了芽細胞胞漿性樹突狀細胞瘤（blastic plasmacytoid dendritic cell neoplasm）。
|
|-
| '''其他急性骨髓性白血病'''
| 包括了未列入上述分類的其他急性骨髓性白血病。

* {{tsl|en|AML with minimal differentiation|極小分化型急性骨髓性白血病}}
* {{tsl|en|AML without maturation|未成熟型急性骨髓性白血病}}
* {{tsl|en|AML with maturation|成熟型急性骨髓性白血病}}
* {{tsl|en|Acute myelomonocytic leukemia|急性骨髓單核球白血病}}
* {{tsl|en|Acute monoblastic and monocytic leukemia|急性單核球母細胞和單核球白血病}}
* {{tsl|en|Acute erythroid leukemia|急性紅血球白血病}}
* {{tsl|en|Acute megakaryoblastic leukemia|急性巨核母細胞白血病}}
* {{tsl|en|Acute basophilic leukemia|急性嗜鹼性球白血病}}
* {{tsl|en|Acute panmyelosis with myelofibrosis|急性全骨髓增生伴骨髓纖維化}}

| {{ICDO|9861|3}}
|}

系統歧異不明之急性白血病（Acute leukemias of ambiguous lineage）又稱為混合表型白血病或[[急性雙表型白血病|急性雙表型白血病]]，指的是白血病細胞無法被分類為骨髓性或淋巴性，或兩類細胞都存在。

===FAB分類===
[[FAB分型|法美英分類]]（French-American-British classification，簡稱FAB）系統將根據白血病細胞的來源和分化程度，將急性骨髓性白血病分為M0到M7等8個亞型。 該分類必須使用[[顯微鏡學|光學顯微鏡]]檢視惡性細胞的外觀或以[[細胞遺傳學|細胞遺傳學]]技術檢驗潛在的染色體變異，不同亞型會有不同的預後及治療成效。雖然WHO分類（見上述）更為實用，但FAB系統仍被廣泛使用。

1976年時提出了最初的六個FAB亞型（M1到M6）<ref>{{cite journal |vauthors=Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C | title = Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group | journal = Br J Haematol | volume = 33 | issue = 4 | pages = 451–8 | year = 1976 | pmid = 188440 | doi = 10.1111/j.1365-2141.1976.tb03563.x }}</ref>，隨後分別在在1985年增加了M7<ref>{{Cite journal|last=Bloomfield|first=C. D.|last2=Brunning|first2=R. D.|date=September 1985|title=FAB M7: acute megakaryoblastic leukemia--beyond morphology|url=https://archive.org/details/sim_annals-of-internal-medicine_1985-09_103_3/page/450|journal=Annals of Internal Medicine|volume=103|issue=3|pages=450–452|issn=0003-4819|pmid=4040724|doi=10.7326/0003-4819-103-3-450}}</ref>、1987年增加了M0<ref>{{Cite journal|last=Lee|first=E. J.|last2=Pollak|first2=A.|last3=Leavitt|first3=R. D.|last4=Testa|first4=J. R.|last5=Schiffer|first5=C. A.|date=November 1987|title=Minimally differentiated acute nonlymphocytic leukemia: a distinct entity|journal=Blood|volume=70|issue=5|pages=1400–1406|issn=0006-4971|pmid=3663939|doi=10.1182/blood.v70.5.1400.bloodjournal7051400}}</ref>。

{| class="wikitable"
|-
!rowspan=2| 分型
!rowspan=2| 名稱
!rowspan=2| 細胞遺傳學
!rowspan=2| 佔成人AML的比例
!colspan=5| 表面抗原<ref>除非在表格中另外指出，其餘的參考資料為下列書籍的[https://books.google.se/books?id=6232pWEM9ZsC&pg=PA97 第97頁] {{Wayback|url=https://books.google.se/books?id=6232pWEM9ZsC&pg=PA97 |date=20210321150305 }}：{{cite book | last=Sun | first=Tsieh | title=Flow cytometry and immunohistochemistry for hematologic neoplasms | publisher=Lippincott Williams & Wilkins | location=Philadelphia | year=2008 | isbn=978-0-7817-8400-9 | oclc=85862340}}</ref>
|-
|{{tsl|en|CD14|CD14}}
|{{tsl|en|CD15|CD15}}
|[[CD33|CD33]]
|{{tsl|en|HLA-DR|HLA-DR}}
|其他
|-
| M0
| {{tsl|en|acute myeloblastic leukemia, minimally differentiated|極小分化型急性骨髓性白血病|急性骨髓性白血病，極小分化型}}
|  
| 5%<ref name=medscape>{{Cite web | last1 = Seiter | first1 = Karen | last2 = Jules | first2 = E Harris | title = Acute Myeloid Leukemia Staging | url = http://emedicine.medscape.com/article/2006750-overview | publisher =  | date = 20 May 2011 | accessdate = 26 August 2011 | archive-date = 2021-03-21 | archive-url = https://web.archive.org/web/20210321150304/https://emedicine.medscape.com/article/2006750-overview | dead-url = no }}</ref>
|style="background: lightpink"|- <ref name=M0>{{cite web|url=http://www.pathologyoutlines.com/topic/leukemiaM0.html|title=Leukemia acute - Acute myeloid leukemia with minimal differentiation (FAB AML M0)|author=Daniela Mihova|website=Pathology Outlines|access-date=2020-07-20|archive-date=2021-02-22|archive-url=https://web.archive.org/web/20210222231520/https://www.pathologyoutlines.com/topic/leukemiaM0.html|dead-url=no}} Topic Completed: 1 March 2013. Minor changes: 19 November 2019}}</ref>
|style="background: lightpink"|- <ref name=M0/>
|style="background: lightgreen"|+ <ref name=M0/>
|style="background: lightgreen"|+ <ref name=M0/>
|[[髓过氧化物酶|MPO]] - <ref name="SalemAbd El-Aziz2011">{{cite journal|last1=Salem|first1=Dalia A.|last2=Abd El-Aziz|first2=Sherin M.|title=Flowcytometric Immunophenotypic Profile of Acute Leukemia: Mansoura Experience|journal=Indian Journal of Hematology and Blood Transfusion|volume=28|issue=2|year=2011|pages=89–96|issn=0971-4502|doi=10.1007/s12288-011-0110-2|pmid=23730015|pmc=3332273}}</ref>
|-
| M1
| {{tsl|en|acute myeloblastic leukemia, without maturation|未成熟型急性骨髓性白血病|急性骨髓性白血病，未成熟型}}
|
| 15%<ref name=medscape/>
|style="background: lightpink"|- 
|style="background: lightpink"|- 
|style="background: lightgreen"|+
|style="background: lightgreen"|+
|[[髓过氧化物酶|MPO]] + <ref name="SalemAbd El-Aziz2011"/>
|-
| M2
| {{tsl|en|acute myeloblastic leukemia, with granulocytic maturation|成熟型急性骨髓性白血病|急性骨髓性白血病，顆粒球成熟型}}
| t(8;21)(q22;q22), t(6;9)
| 25%<ref name=medscape/>
|style="background: lightpink"|- 
|style="background: lightgreen"|+
|style="background: lightgreen"|+
|style="background: lightgreen"|+
|
|-
| M3
| 前骨髓細胞或{{tsl|en|acute promyelocytic leukemia|急性前骨髓細胞白血病}}（APL）
| t(15;17)
| 10%<ref name=medscape/>
|style="background: lightpink"|- 
|style="background: lightgreen"|+
|style="background: lightgreen"|+
|style="background: lightpink"|-
|
|-
| M4
| {{tsl|en|acute myelomonocytic leukemia|急性骨髓單核球白血病}}
| inv(16)(p13q22), del(16q)
| 20%<ref name=medscape/>
| <45%
|style="background: lightgreen"|+
|style="background: lightgreen"|+
|style="background: lightgreen"|+
|
|-
| M4eo
| 骨髓單核球白血病併骨髓內[[嗜酸性粒細胞|嗜酸性球]]增生
| inv(16), t(16;16)
| 5%<ref name=medscape/>
| +/- <ref name="Adriaansente Boekhorst1993">Partial expression: {{cite journal|last1=Adriaansen|first1=HJ|last2=te Boekhorst|first2=PA|last3=Hagemeijer|first3=AM|last4=van der Schoot|first4=CE|last5=Delwel|first5=HR|last6=van Dongen|first6=JJ|title=Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression|journal=Blood|volume=81|issue=11|year=1993|pages=3043–3051|issn=0006-4971|doi=10.1182/blood.V81.11.3043.bloodjournal81113043|pmid=8098967}}</ref>
|
|style="background: lightgreen"|+ <ref name=M4eo>[https://books.google.se/books?id=1xnF4Re7MC8C&pg=PA99 Page 99] {{Wayback|url=https://books.google.se/books?id=1xnF4Re7MC8C&pg=PA99 |date=20201126072123 }} in: {{cite book | last=Sun | first=Tsieh | title=Atlas of hematologic neoplasms | publisher=Springer | location=Dordrecht New York | year=2009 | isbn=978-0-387-89848-3 | oclc=432709321}}</ref>
|style="background: lightgreen"|+ <ref name=M4eo/>
| {{tsl|en|CD2||CD2}}+ <ref name=M4eo/>
|-
| M5
| {{tsl|en|acute monoblastic leukemia|急性單核球母細胞白血病}}（M5a）或急性單核球白血病（M5b）
| del (11q), t(9;11), t(11;19)
| 10%<ref name=medscape/>
|style="background: lightgreen"| >55%
|style="background: lightgreen"|+
|style="background: lightgreen"|+
|style="background: lightgreen"|+
|
|-
| M6
| {{tsl|en|acute erythroid leukemia|急性紅血球性白血病}}，包含紅血球白血病（M6a）和非常罕見的紅血球樣白血病（M6b）
| 
| 5%<ref name=medscape/>
|style="background: lightpink"| -
| +/-
| +/-
| +/-
| {{tsl|en|Glycophorin|血型糖蛋白|Glycophorin}} +
|-
| M7
| {{tsl|en|acute megakaryoblastic leukemia|急性巨核母細胞白血病}}
| t(1;22)
| 5%<ref name=medscape/>
|style="background: lightpink"| -
|style="background: lightpink"| -
|style="background: lightgreen"|+
| +/-
| {{tsl|en|Integrin alpha 2b|CD41|CD41}}/[[CD61|CD61]]+
|}

急性骨髓性白血病的形態學分型也包含了少數未列於FAB分型中的亞型，例如{{tsl|en|acute basophilic leukemia|急性嗜鹼性性球白血病}}，這種類型曾在1999年被建議增列為第9個亞型（M8）<ref>{{cite journal |vauthors=Duchayne E, Demur C, Rubie H, Robert A, Dastugue N | title = Diagnosis of acute basophilic leukemia | journal = Leuk Lymphoma | volume = 32 | issue = 3–4 | pages = 269–78 | year = 1999 | pmid = 10037024 | doi = 10.3109/10428199909167387 }}</ref>。

==病生理學==
[[File:Diagram_showing_the_cells_in_which_AML_starts_CRUK_297.svg|thumb]]
急性骨髓性白血病中的惡性細胞為{{tsl|en|myeloblast|骨髓母細胞}}，在正常的[[造血作用|造血]]過程中，骨髓母細胞是[[髓細胞|骨髓性]]白血球不成熟的前驅細胞，而正常的骨髓母細胞則會慢慢分化為成熟的白血球。但在急性骨髓性白血病，由於骨髓母細胞基因突變造成細胞不[[细胞分化|分化]]而一直維持在不成熟的狀態<ref>{{cite journal | author = Fialkow PJ | title = Clonal origin of human tumors | journal = Biochim. Biophys. Acta | volume = 458 | issue = 3 | pages = 283–321 | year = 1976 | pmid = 1067873 | doi = 10.1016/0304-419X(76)90003-2 }}</ref>。這樣的突變本身不會造成白血病，但當這種不分化的問題[[二次打击学说|合併其他突變]]，使得細胞的{{tsl|en|cell growth|細胞增生|增生}}不受控制時，單一種不成熟的細胞便會大量產生，造成急性骨髓性白血病<ref>{{cite journal |vauthors=Fialkow PJ, Janssen JW, Bartram CR | title = Clonal remissions in acute nonlymphocytic leukemia: evidence for a multistep pathogenesis of the malignancy | journal = Blood | volume = 77 | issue = 7 | pages = 1415–7 | date = 1 April 1991 | pmid = 2009365 | doi = 10.1182/blood.V77.7.1415.1415 }}</ref>。

由於白血球分化中的任何步驟都可能發生癌變，使得急性骨髓性白血病擁有豐富的多樣性與異質性<ref>{{cite journal |vauthors=Bonnet D, Dick JE | title = Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell | journal = Nat. Med. | volume = 3 | issue = 7 | pages = 730–7 | year = 1997 | pmid = 9212098 | doi = 10.1038/nm0797-730 }}</ref>。現代的分類系統依據白血病細胞的分化程度進行分類，認為其表現和特徵會受到分化程度的影響。

許多急性骨髓性白血病患者的癌細胞有特定的[[細胞遺傳學|細胞遺傳學]]特徵，這些染色體異常的種類常對疾病的[[預後|預後]]有重要影響<ref>Abeloff, Martin et al. (2004), pp. 2831–32.</ref>。[[染色體易位|轉位的染色體]]會產生不正常的融合蛋白，當[[轉錄因子|轉錄因子]]因為行程融合蛋白而改變了其性質時便可能造成白血病細胞停止<ref>{{cite book|editor=Greer JP|title= Wintrobe's Clinical Hematology|edition=11th|location=Philadelphia|publisher= Lippincott, Williams, and Wilkins|year= 2004|pages=2045–2062|isbn=978-0-7817-3650-3|display-editors=etal}}</ref>。舉例來說，急性前骨髓細胞白血病中因為t(15;17)轉位而形成PML-RARα[[融合蛋白|融合蛋白]]，此蛋白會結合到{{tsl|en|retinoic acid|視黃酸}}受體元件上，而該元件位於許多骨髓相關基因的啟動子中，因此會抑制骨髓細胞的分化<ref>{{cite journal |vauthors=Melnick A, Licht JD | title = Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia |url=https://archive.org/details/sim_blood_1999-05-15_93_10/page/3167 | journal = Blood | volume = 93 | issue = 10 | pages = 3167–215 | date = 15 May 1999 | pmid = 10233871 | doi = 10.1182/blood.V93.10.3167.410k44_3167_3215 }}</ref>。

急性骨髓性白血病的[[醫學徵象|徵象]]和症狀來自於白血病細胞的大量增生，從而取代並干擾骨髓中正常的血液細胞發展<ref>Abeloff, Martin et al. (2004), p. 2828.</ref>，這將造成[[嗜中性白血球低下|嗜中性球低下]]、[[貧血|貧血]]和{{tsl|en|thrombocytopenia|血小板低下}}，急性骨髓性白血病的症狀因此常和正常血液細胞低下有關。少數患者的白血病細胞可能會在骨髓以外的地方聚集成一個腫塊，稱為{{tsl|en|chloroma|綠色瘤}}，症狀依其位置有所不同<ref name="symptoms"/>。

產生白血病細胞的一個重要並生理機轉為表觀遺傳學調控，特定的基因突變可能改變某些表觀遺傳酵素的功能，進而使得白血病細胞去分化<ref name=":0">{{Cite journal|title = Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms|journal = Leukemia|pages = 2134–2142|volume = 29|issue = 11|doi = 10.1038/leu.2015.91|first = R J|last = Molenaar|first2 = S|last2 = Thota|first3 = Y|last3 = Nagata|first4 = B|last4 = Patel|first5 = M|last5 = Clemente|first6 = B|last6 = Przychodzen|first7 = C|last7 = Hirsh|first8 = A D|last8 = Viny|first9 = N|last9 = Hosano|pmid=25836588|pmc = 5821256|year = 2015}}</ref>。例如代謝酵素IDH1和IDH2的突變會產生新的致癌代謝物''D''-2-2-羥基戊二酸（hydroxyglutarate），該代謝物會抑制DNA去甲基酶TET2的活性，而TET2則為一種表觀遺傳酵素<ref>{{Cite journal|title = The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation|journal = Biochimica et Biophysica Acta (BBA) - Reviews on Cancer|date = 1 December 2014|pages = 326–341|volume = 1846|issue = 2|doi = 10.1016/j.bbcan.2014.05.004|first = Remco J.|last = Molenaar|first2 = Tomas|last2 = Radivoyevitch|first3 = Jaroslaw P.|last3 = Maciejewski|first4 = Cornelis J. F.|last4 = van Noorden|first5 = Fonnet E.|last5 = Bleeker|pmid=24880135}}</ref>。目前的假說認為表觀遺傳學改變可能會造成抑癌基因被抑制或致癌基因被活化<ref>{{Cite journal|last=Sharma|first=Shikhar|last2=Kelly|first2=Theresa K.|last3=Jones|first3=Peter A.|date=2010|title=Epigenetics in cancer|journal=Carcinogenesis|volume=31|issue=1|pages=27–36|doi=10.1093/carcin/bgp220|issn=0143-3334|pmc=2802667|pmid=19752007}}</ref>。

==治療==
急性骨髓性白血病的第一線治療為[[化學治療|化學治療]]，療程分為兩個階段：誘導性化學治療和鞏固性化學治療。誘導性化學治療的目的是使白血病細胞數目減少到偵測不到，達到完全緩解（complete remission）；而鞏固性化學治療則是要消除殘餘偵測不到的癌細胞，使疾病痊癒<ref>{{cite web|url=http://www.mountsinai.org/patient-care/health-library/diseases-and-conditions/acute-myelogenous-leukemia-adult|title=Acute myeloid leukemia|archive-url=https://web.archive.org/web/20120807180920/http://www.mountsinai.org/patient-care/health-library/diseases-and-conditions/acute-myelogenous-leukemia-adult|archive-date=7 August 2012 | publisher= The Mount Sinai Hospital|date=September 2011}}</ref>。若誘導性化學治療失敗或之後再復發，則須考慮造血幹細胞移植，而針對特定高風險的類型，造血幹細胞移植有時也會作為第一線治療。目前[[酪氨酸激酶抑制劑|酪氨酸激酶抑制劑]]相關的新藥研究也正開發中<ref name="pmid_23631653">{{Citation |last=Kayser |first=S |last2=Levis |first2=MJ |year=2014 |title=FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations |journal=Leuk Lymphoma |volume=55 |issue=2 |pages=243–255 |pmid=23631653 |pmc=4333682 |doi=10.3109/10428194.2013.800198 |postscript=.}}</ref>。

===誘導期===
除了M3以外的所有FAB分型通常都會給予[[阿糖胞苷|阿糖胞苷]]（cytarabine，簡稱ara-C）和[[蒽环类药物|蒽环类药物]]（anthracycline）為主的{{tsl|en|induction chemotherapy|誘導性化學治療}}，其中最常用的蒽环类药物為[[道諾黴素|道諾黴素]]（daunorubicin）<ref name="treatment">Abeloff, Martin et al. (2004), pp. 2835–39.</ref>。最知名的誘導性化學治療是稱為「{{tsl|en|7+3 (chemotherapy)|7+3 (化學治療)|7+3}}」（或稱「3+7」）的處方，這是因為該處方中的ara-C須連續靜脈滴注7天，蒽环类药物則須靜脈推注三天。高達70%的急性骨髓性白血病患者在上述配方的治療後能達到緩解<ref>{{cite journal | author = Bishop JF | title = The treatment of adult acute myeloid leukemia | url = https://archive.org/details/sim_seminars-in-oncology_1997-02_24_1/page/57 | journal = Semin Oncol | volume = 24 | issue = 1 | pages = 57–69 | year = 1997 | pmid = 9045305 }}</ref>。其他的誘導性化學治療配方還包括單用高劑量ara-C、{{tsl|en|R-HDAC|R-HDAC}}（併用高劑量ara-C和[[利妥昔單抗|莫須瘤]]）、{{tsl|en|FLAG (chemotherapy)|FLAG（化學治療）|FLAG為基礎的配方}}或其他研發中的藥物<ref>{{cite journal |vauthors=Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M | title = A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study |url=https://archive.org/details/sim_blood_1996-10-15_88_8/page/2841 | journal = Blood | volume = 88 | issue = 8 | pages = 2841–51 | date = 15 October 1996 | pmid = 8874180 | doi = 10.1182/blood.V88.8.2841.bloodjournal8882841 }}</ref><ref>{{cite journal | vauthors = Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van Der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S | title = A randomized study of high-dose cytarabine in induction in acute myeloid leukemia | url = https://archive.org/details/sim_blood_1996-03-01_87_5/page/1710 | journal = Blood | volume = 87 | issue = 5 | pages = 1710–7 | date = 1 March 1996 | pmid = 8634416 | doi = 10.1182/blood.V87.5.1710.1710 }}</ref>。由於化療本身的毒性（例如[[骨髓抑制|骨髓抑制]]）和免疫力降低後增加的感染風險，年長的患者可能無法接受誘導性化療，對於此類患者，可能需使用強度較低的化學治療或[[临终关怀|緩和醫療]]。

M3亞型的急性骨髓性白血病又稱為{{tsl|en|acute promyelocytic leukemia|急性前骨髓細胞白血病}}（APL），其治療方法則可以單用[[三氧化二砷|三氧化二砷]]（ATO)
<ref>{{Cite journal|last=Iland|first=Harry J.|last2=Seymour|first2=John F.|date=June 2013|title=Role of arsenic trioxide in acute promyelocytic leukemia|journal=Current Treatment Options in Oncology|volume=14|issue=2|pages=170–184|doi=10.1007/s11864-012-0223-3|issn=1534-6277|pmid=23322117|hdl=11343/219801}}</ref><ref>{{Cite journal|last=Alimoghaddam|first=Kamran|date=2014-07-01|title=A Review of Arsenic Trioxide and Acute Promyelocytic Leukemia|journal=International Journal of Hematology-Oncology and Stem Cell Research|volume=8|issue=3|pages=44–54|issn=2008-3009|pmc=4305381|pmid=25642308}}</ref>或全反式[[維A酸|視黃酸]]（ATRA）搭配誘導性化療（通常是搭配蒽環類藥物）<ref>{{cite journal |vauthors=Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY | title = Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia | journal = Blood | volume = 72 | issue = 2 | pages = 567–72 | date = 1 August 1988 | pmid = 3165295 | doi=10.1182/blood.V72.2.567.567}}</ref><ref>{{cite journal |vauthors=Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH | title = All-trans-retinoic acid in acute promyelocytic leukemia | journal = N. Engl. J. Med. | volume = 337 | issue = 15 | pages = 1021–8 | year = 1997 | pmid = 9321529 | doi = 10.1056/NEJM199710093371501 }}</ref><ref>{{cite journal |vauthors=Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L | title = A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group |url=https://archive.org/details/sim_blood_1999-08-15_94_4/page/1192 | journal = Blood | volume = 94 | issue = 4 | pages = 1192–200 | date = 15 August 1999 | pmid = 10438706 | doi = 10.1182/blood.V94.4.1192 }}</ref>。由於治療時前骨髓細胞可能會將細胞內的顆粒物質釋放到血液中，因此治療時須注意預防[[弥散性血管内凝血|弥散性血管内凝血]]（DIC）的產生。APL的預後非常良好，在現行建議的療法下通常可完全治癒。

誘導期的目的為使疾病達到完全緩解，但完全緩解並不代表疾病已經治癒；相反地，完全緩解只強調在現有的檢測方法下沒有惡性細胞被偵測到<ref name="treatment"/>。新診斷的成人急性骨髓性白血病約有50%–75%能達到完全緩解，但此數值受上述諸多預後因子的影響而有不同<ref>{{cite journal | author = Estey EH | title = Treatment of acute myelogenous leukemia | journal = Oncology (Williston Park) | volume = 16 | issue = 3 | pages = 343–52, 355–6; discussion 357, 362, 365–6 | year = 2002 | pmid = 15046392 }}</ref>。緩解持續的期間取決於白血病本身的種類，但一般而言，所有未接受鞏固治療的疾病都會再復發<ref name="MChemotherapy">{{cite journal |vauthors=Cassileth PA, Harrington DP, Hines JD, Oken MM, Mazza JJ, McGlave P, Bennett JM, O'Connell MJ | title = Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia | journal = J Clin Oncol | volume = 6 | issue = 4 | pages = 583–7 | year = 1988 | pmid = 3282032 | doi = 10.1200/JCO.1988.6.4.583 }}</ref>。

===鞏固期===
即便白血病在治療後達到了完全緩解，仍會有少量現在的檢測方法也無法偵測出的白血病細胞殘存；若在緩解其後沒有更進一步的進行治療，幾乎所有急性骨髓性白血病都會再度復發<ref name="MChemotherapy" />，因此鞏固性化學治療的目的就是要消除這些偵測不到的疾病，以預防復發、達成痊癒。

白血病緩解後的治療方式取決於患者本身的預後因子（見上述）和整體健康狀況。針對預後較佳的白血病（如inv(16)、t(8;21)和t(15;17)），患者一般會在接受三至五個療程的密集化學治療，即鞏固性化療<ref>{{cite journal |vauthors=Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E | title = Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B | journal = N. Engl. J. Med. | volume = 331 | issue = 14 | pages = 896–903 | year = 1994 | pmid = 8078551 | doi = 10.1056/NEJM199410063311402 }}</ref><ref name="nccn">{{cite journal |vauthors=Appelbaum FR, Baer MR, Carabasi MH, Coutre SE, Erba HP, Estey E, Glenn MJ, Kraut EH, Maslak P, Millenson M, Miller CB, Saba HI, Stone R, Tallman MS | title = NCCN Practice Guidelines for Acute Myelogenous Leukemia | journal = Oncology (Williston Park, N.Y.) | volume = 14 | issue = 11A | pages = 53–61 | year = 2000 | pmid = 11195419 }}</ref>；至於較容易復發的白血病（如帶高風險的細胞遺傳學特徵、原本患有骨髓增生異常症候群或治療相關的急性白血病），若患者有合適的捐贈者且健康狀況允許的話，一般會建議進行異體[[骨髓移植|造血幹細胞移植]]。針對中度風險的急性骨髓性白血病（細胞遺傳學正常或沒有列入低風險和高風險之列），疾病緩解後的最佳療法目前沒有定論，須視患者年紀、整體健康狀況、患者決定、是否有合適的幹細胞捐贈者而定<ref name="nccn"/>。

對於不適合進行幹細胞移植的患者，在鞏固期化療完成後可給予結合二鹽酸組織胺（{{tsl|en|Ceplene|Ceplene}}）和[[白细胞介素-2|介白素-2]]（Proleukin）的免疫療法，該療法已被證實能減少14%的復發率，並增加將近50%的長期緩解率<ref>{{cite journal |vauthors=Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, Hogge DE, Nilsson B, Or R, Romero AI, Rowe JM, Simonsson B, Spearing R, Stadtmauer EA, Szer J, Wallhult E, Hellstrand K | title = Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial | journal = Blood | volume = 108 | issue = 1 | pages = 88–96 | date = July 2006 | pmid = 16556892 | doi = 10.1182/blood-2005-10-4073 }}</ref>。

===疾病復發===
對於復發的急性骨髓性白血病，目前唯一證實有效的根治性療法只有[[骨髓移植|造血幹細胞移植]]，特別是還沒進行過造血幹細胞移植的患者<ref name="relapse">Abeloff, Martin et al. (2004), pp. 2840–41.</ref><ref>{{cite journal | author = Appelbaum FR | title = Editorial: Who should be transplanted for AML? | journal = Leukemia | volume = 15 | issue = 4 | pages = 680–2 | year = 2001 | pmid = 11368380 | doi = 10.1038/sj/leu/2402074 }}</ref><ref>{{cite journal | author = Appelbaum FR | title = Keynote address: hematopoietic cell transplantation beyond first remission | journal = Leukemia | volume = 16 | issue = 2 | pages = 157–9 | year = 2002 | pmid = 11840278 | doi = 10.1038/sj.leu.2402345 }}</ref>。美國在2000年核准了連接[[单克隆抗体|單株抗體]]的胞殺性物質{{tsl|en|gemtuzumab ozogamicin||gemtuzumab ozogamicin}}（Mylotarg），用於治療60歲以上、AML復發且不適合高劑量化學治療的患者<ref>{{cite journal |vauthors=Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR | title = Efficacy and safety of gemtuzumab ozogamicin in people with CD33-positive acute myeloid leukemia in first relapse |url=https://archive.org/details/sim_journal-of-clinical-oncology_2001-07-01_19_13/page/3244 | journal = J. Clin. Oncol. | volume = 19 | issue = 13 | pages = 3244–54 | date = 1 July 2001 | pmid = 11432892 | doi = 10.1200/JCO.2001.19.13.3244 }}</ref>，該藥物在2010年尤其製造商輝瑞藥廠自主下架，但又在2010年時根據新的實驗資料重新上市<ref>{{Cite web |url=http://www.pfizer.com/files/products/mylotarg_hcp_letter.pdf |title=存档副本 |access-date=2020-07-20 |archive-date=2015-09-24 |archive-url=https://web.archive.org/web/20150924072718/http://www.pfizer.com/files/products/mylotarg_hcp_letter.pdf |dead-url=no }}</ref><ref>{{cite web| url=https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm574507.htm| title=Press Announcements - FDA approves Mylotarg for treatment of acute myeloid leukemia| date=30 November 2018| access-date=2020-07-20| archive-date=2019-04-25| archive-url=https://web.archive.org/web/20190425032135/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574507.htm| dead-url=no}}</ref>。

由於急性骨髓性白血病的治療選項有限，因此[[临终关怀|緩和醫療]]或加入[[臨床試驗|臨床試驗]]也是相當重要的考量。

==預後==
[[File:Survival_curve_by_age_at_diagnosis_-_cancer_seer_gov_-_faststats.jpg|thumb]]
[[Image:9;11.rhyax.jpg|thumb]]
急性骨髓性白血病是一種可被治癒的疾病，患者能被治癒的機率取決於數項預後因子<ref name="prog">{{cite journal | author = Estey EH | title = Prognostic factors in acute myelogenous leukemia | journal = Leukemia | volume = 15 | issue = 4 | pages = 670–2 | year = 2001 | pmid = 11368376 | doi = 10.1038/sj/leu/2402057 }}</ref>。

===細胞遺傳學===
急性骨髓性白血病單一最重要的預後因子就是[[細胞遺傳學|細胞遺傳學]]，即白血病細胞的染色體結構。特定的細胞遺傳異常和特別好的預後有關，例如急性前骨髓性白血病的t(15;17)轉位；約有一半的急性骨髓性白血病有「正常」的細胞遺傳學，也就是具有中度的風險；一些其他的細胞遺傳學變異岞和較差的預後和較高的治療後復發率有關<ref>{{cite journal |vauthors=Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, Rees JK, Stevens RF, Walker H | title = A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties |url=https://archive.org/details/sim_british-journal-of-haematology_1999-10_107_1/page/69 | journal = Br J Haematol | volume = 107 | issue = 1 | pages = 69–79 | year = 1999 | pmid = 10520026 | doi = 10.1046/j.1365-2141.1999.01684.x }}</ref><ref>{{cite journal |vauthors=Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR | title = Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study |url=https://archive.org/details/sim_blood_2000-12-15_96_13/page/4075 | journal = Blood | volume = 96 | issue = 13 | pages = 4075–83 | date = 15 December 2000 | pmid = 11110676 | doi = 10.1182/blood.V96.13.4075 }}</ref><ref name="Byrd 2002">{{cite journal |vauthors=Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD | title = Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) | journal = Blood | volume = 100 | issue = 13 | pages = 4325–36 | year = 2002 | pmid = 12393746 | doi = 10.1182/blood-2002-03-0772 | url = https://semanticscholar.org/paper/97d297906589b1716b0adb65b98e49192298bd9d }}</ref>。

MRC臨床試驗是第一個發表細胞遺傳學與預後間關聯的研究，其中提到的細胞遺傳變異分類如下：<ref>{{cite journal |vauthors=Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A | title = The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties |url=https://archive.org/details/sim_blood_1998-10-01_92_7/page/2322 | journal = Blood | volume = 92 | issue = 7 | pages = 2322–33 | date = 1 October 1998 | pmid = 9746770 | doi = 10.1182/blood.V92.7.2322 }}</ref>
{| class="wikitable"
|-
!風險類別
!變異
!五年存活率
!復發率
|-
|佳（Good）
|t(8;21)、t(15;17)、inv(16)
|70%
|33%
|-
|中度（Intermediate）
|正常、+8、+21、+22、del(7q)、del(9q)、異常的11q23、其他結構或套數變化
|48%
|50%
|-
|差（Poor）
| −5、−7、del(5q)、異常的3q、複雜染色體Complex cytogenetics
|15%
|78%
|-
|}

其後，美國{{tsl|en|Southwest Oncology Group|西南癌症組織}}、{{tsl|en|Eastern Cooperative Oncology Group|東岸癌症合作組織}}<ref>{{cite journal |vauthors=Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR | title = Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study | journal = Blood | volume = 96 | issue = 13 | pages = 4075–83 | year = 2000 | pmid = 11110676 | doi = 10.1182/blood.V96.13.4075 }}</ref>、和更之後的{{tsl|en|Cancer and Leukemia Group B|癌症與白血病組織B}}也陸續發表了其他細胞遺傳學與其預後之關聯的文獻<ref name="Byrd 2002"/>。

===骨髓增生異常症候群===
如同化療或其他惡性腫瘤導致的急性骨髓性白血病，由[[骨髓增生异常综合征|骨髓增生異常症候群]]（MDS）或[[骨髓增殖性疾病|骨髓增殖性疾病]]導致的急性骨髓性白血病（俗稱次發性白血病）的[[預後|預後]]較差，這些類型的急性骨髓性白血病通常有不佳的細胞遺傳學異常<ref>{{cite journal |vauthors=Thirman MJ, Larson RA | title = Therapy-related myeloid leukemia | journal = Hematol Oncol Clin North Am | volume = 10 | issue = 2 | pages = 293–320 | year = 1996 | pmid = 8707757 | doi = 10.1016/S0889-8588(05)70340-3 }}</ref><ref>{{cite journal |vauthors=Rowley JD, Golomb HM, Vardiman JW | title = Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease | journal = Blood | volume = 58 | issue = 4 | pages = 759–67 | date = 1 October 1981 | pmid = 7272506 | doi = 10.1182/blood.V58.4.759.759 }}</ref><ref>{{cite journal |vauthors=Lee JT, Lee JD, Choe KO, Yang WI | title = Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia | journal = Blood | volume = 99 | issue = 6 | pages = 1909–12 | year = 2002 | pmid = 11877259 | doi = 10.1182/blood.V99.6.1909 | url = https://semanticscholar.org/paper/f77795e4341dd22563276323b130cd8b2b867614 }}</ref>。

===其他生物指標===
在一些研究中，年紀大於60歲或[[乳酸脱氢酶|乳酸脱氢酶]]（LDH）升高和較差的預後有關<ref>{{cite journal |vauthors=Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig WD, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Grüneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wörmann B, Heinecke A, Sauerland MC, Büchner T, Hiddemann W | title = Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies | journal = J. Clin. Oncol. | volume = 21 | issue = 2 | pages = 256–65 | year = 2003 | pmid = 12525517 | doi = 10.1200/JCO.2003.08.005 }}</ref>；和大多數的癌症一樣，{{tsl|en|performance status|日常體能狀態}}（如整體身體狀態和活動能力）也對預後有很大的影響。急性骨髓性白血病整體的五年存活率約為25%，60歲以下的患者佔了整體的40%，但只有10%能在診斷後存活超過五年<ref name=":1">{{Cite book|url=https://books.google.com/books?id=JoIlAgAAQBAJ|title=Harrisons Manual of Oncology 2/E|last=Chabner|first=Bruce A.|last2=Lynch|first2=Thomas J.|last3=Longo|first3=Dan L.|date=22 March 2014|publisher=McGraw Hill Professional|isbn=9780071793261|location=|pages=294|language=en|access-date=2020-07-20|archive-date=2020-11-26|archive-url=https://web.archive.org/web/20201126072153/https://books.google.com/books?id=JoIlAgAAQBAJ|dead-url=no}}</ref>。

====基因型====
許多分子突變對急性骨髓性白血病預後的影響正被學者研究當中；但目前為止，只有''FLT3-ITD''、''NPM1''、''CEBPA''和''c-KIT''被列入國際風險分級的評估之中，但更多的突變在未來很可能被列入<ref name="NEJM2015"/>。''{{tsl|en|FLT3|FLT3}}''基因的內部串聯重複序列（ITDs）已被證實會造成較差的預後，一些{{tsl|en|FLT3 inhibitor|FLT3抑制劑}}正在進行臨床試驗，目前結果有好有壞。另外兩個突變——''{{tsl|en|NPM1||NPM1}}''和''{{tsl|en|CEBPA||CEBPA}}''則和較佳的預後有關，在細胞遺傳學正常的患者中尤為如此，這兩個突變已列入目前的風險分級當中<ref name="NEJM2015"/>。

''{{tsl|en|CD117||c-KIT}}''突變對急性骨髓性白血病的臨床重要性還在研究當中，因為該突變在藥理學上有已上市的{{tsl|en|tyrosine kinase inhibitors|酪胺酸激酶抑制劑}}——如[[伊马替尼|伊马替尼]]（imatinib）和[[舒尼替尼|舒尼替尼]]（sunitinib）——可供使用，因此這方面的研究十分盛行。<ref name="NEJM2015"/>''{{tsl|en|RUNX1||RUNX1}}''、''{{tsl|en|ASXL1||ASXL1}}''、''[[P53|TP53]]''等突變和較差的治療效果有關，在不久的將來也可能會列入疾病的風險分級當中；至於''{{tsl|en|DNMT3A||DNMT3A}}''、''{{tsl|en|IDH1||IDH1}}''、''{{tsl|en|IDH2||IDH2}}'') 等突變對預後的影響則相對較不明朗<ref name=":0" /><ref name="NEJM2015"/>。

===治癒率===
急性骨髓性白血病在臨床試驗中的治癒率約為20–45%<ref>{{cite journal |vauthors=Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH | title = Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission | journal = N. Engl. J. Med. | volume = 339 | issue = 23 | pages = 1649–56 | year = 1998 | pmid = 9834301 | doi = 10.1056/NEJM199812033392301 }}</ref><ref>{{cite journal | vauthors = Matthews JP, Bishop JF, Young GA, Juneja SK, Lowenthal RM, Garson OM, Cobcroft RG, Dodds AJ, Enno A, Gillett EA, Hermann RP, Joshua DE, Ma DD, Szer J, Taylor KM, Wolf M, Bradstock KF | title = Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia | url = https://archive.org/details/sim_british-journal-of-haematology_2001-06_113_3/page/727 | journal = Br. J. Haematol. | volume = 113 | issue = 3 | pages = 727–36 | year = 2001 | pmid = 11380464 | doi = 10.1046/j.1365-2141.2001.02756.x }}</ref>，但臨床試驗的受試者通常為較年輕或能承受高強度治療的患者；因此整體的治癒率（包括老人和無法接受高強度治療的患者）可能較低。急性前骨髓性白血病的治癒率則高達98%<ref>{{cite journal | vauthors = Sanz MA, Lo Coco F, Martín G, Avvisati G, Rayón C, Barbui T, Díaz-Mediavilla J, Fioritoni G, González JD, Liso V, Esteve J, Ferrara F, Bolufer P, Bernasconi C, Gonzalez M, Rodeghiero F, Colomer D, Petti MC, Ribera JM, Mandelli F | title = Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups | journal = Blood | volume = 96 | issue = 4 | pages = 1247–53 | date = 15 August 2000 | pmid = 10942364 | url = http://bloodjournal.hematologylibrary.org/cgi/content/full/96/4/1247 | author =  | access-date = 2020-07-20 | archive-url = https://web.archive.org/web/20100527064934/http://bloodjournal.hematologylibrary.org/cgi/content/full/96/4/1247 | archive-date = 2010-05-27 | dead-url = yes }}</ref>。

===疾病復發===
急性骨髓性白血病很常復發，復發後的預後通常較差<ref name=":1" />；復發後極少能夠達成長期存活，目前唯一已知的案例為{{tsl|en|Marie-Marguerite d'Youville||馬利-瑪格麗特·德尤維爾}}<ref>{{Cite news|url=https://www.nytimes.com/2016/09/06/opinion/pondering-miracles-medical-and-religious.html|title=Pondering Miracles, Medical and Religious|last=Duffin|first=Jacalyn|date=5 September 2016|work=The New York Times|access-date=12 March 2018|language=en-US|issn=0362-4331|archive-date=2021-03-21|archive-url=https://web.archive.org/web/20210321150425/https://www.nytimes.com/2016/09/06/opinion/pondering-miracles-medical-and-religious.html|dead-url=no}}</ref>。

==流行病學==
急性骨髓性白血病是一種相對少見的癌症，美國每年約有10,500名新發案例，[[發病率|發生率]]從1995年到2005年都維持穩定，佔了癌症死亡人數的1.2%<ref name="cancerstats">{{cite journal |vauthors=Jemal A, Thomas A, Murray T, Thun M | title = Cancer statistics, 2002 | journal = CA Cancer J Clin | volume = 52 | issue = 1 | pages = 23–47 | year = 2002 | pmid = 11814064 | doi = 10.3322/canjclin.52.1.23 }}</ref>。在英國則佔了所有白血病的34%，2011年約有2,900人被診斷出此疾病<ref>{{cite web |title=Acute myeloid leukaemia (AML) statistics |url=http://www.cancerresearchuk.org/cancer-info/cancerstats/types/leukaemia-aml/ |website=Cancer Research UK |accessdate=27 October 2014 |archive-date=2015-05-12 |archive-url=https://web.archive.org/web/20150512093542/http://www.cancerresearchuk.org/cancer-info/cancerstats/types/leukaemia-aml/ |dead-url=no }}</ref>。

急性骨髓性白血病的發生率隨年紀增加，診斷年齡中位數為63歲。急性骨髓性白血病佔了成人急性白血病的90%，但在孩童則相當少見<ref name="cancerstats"/>。治療相關的白血病（即肇因於先前的化學治療）的發生率正在增加，目前約佔了急性骨髓性白血病的10–20%<ref>{{cite journal | vauthors = Leone G, Mele L, Pulsoni A, Equitani F, Pagano L | title = The incidence of secondary leukemias | journal = Haematologica | volume = 84 | issue = 10 | pages = 937–45 | date = 1 October 1999 | pmid = 10509043 | url = http://www.haematologica.org/cgi/reprint/84/10/937 | access-date = 2020-07-20 | archive-date = 2011-10-02 | archive-url = https://web.archive.org/web/20111002154823/http://www.haematologica.org/cgi/reprint/84/10/937 | dead-url = no }}</ref>。男性的發生率略高於女性，比例約為1.3：1<ref>{{cite journal |vauthors=Greenlee RT, Hill-Harmon MB, Murray T, Thun M | title = Cancer statistics, 2001 | journal = CA Cancer J Clin | volume = 51 | issue = 1 | pages = 15–36 | year = 2001 | pmid = 11577478 | doi = 10.3322/canjclin.51.1.15 }}</ref>。

急性骨髓性白血病的發生率有一些地理分布的差異，北美、歐洲和大洋洲的成人發生率最高，亞洲和拉丁美洲則較少<ref>{{cite book |author=Linet MS |editor=Lilienfeld AM |title=Monographs in Epidemiology and Biostatistics |year=1985 |publisher=Oxford University Press |location=New York |isbn=978-0-19-503448-6 |chapter=The leukemias: Epidemiologic aspects. |page=[https://archive.org/details/leukemiasepidemi00line/page/ I] |chapter-url=https://archive.org/details/leukemiasepidemi00line |url=https://archive.org/details/leukemiasepidemi00line/page/ }}</ref><ref>{{cite book|author=Aoki K|title=Death Rates for Malignant Neoplasms for Selected Sites by Sex and Five-Year Age Group in 33 Countries 1953–57 to 1983–87|location=Nagoya, Japan|publisher=University of Nagoya Press, International Union Against Cancer|year=1992|author2=Kurihars M|author3=Hayakawa N}}</ref>；相反地，兒童的發生率則是北美和印度比亞洲其他地方少<ref>{{cite journal |vauthors=Bhatia S, Neglia JP | title = Epidemiology of childhood acute myelogenous leukemia | journal = J. Pediatr. Hematol. Oncol. | volume = 17 | issue = 2 | pages = 94–100 | year = 1995 | pmid = 7749772 | doi = 10.1097/00043426-199505000-00002 }}</ref>。這樣的差異可能與[[群体遗传学|族群遺傳]]、{{tsl|en|environmental factor|環境因素}}或上述兩者的結合有關。

==歷史==
[[Image:Alfred_Velpeau_01.JPG|thumb]]
第一個紀錄白血病的醫學文獻可以追溯到1827年由法國醫師{{tsl|en|Alfred-Armand-Louis-Marie Velpeau||Alfred-Armand-Louis-Marie Velpeau}}診治的一名63歲患者，該患者有發燒、虛弱、[[腎結石|腎結石]]和明顯的{{tsl|en|hepatosplenomegaly|肝脾腫大}}，Velpeau注意到這名患者的血液相當黏稠如膠水一般，並猜測是白血球（white corpuscles）造成的<ref>Hoffman ''et al.'' 2005, p. 1071.</ref>。1845年，[[爱丁堡|爱丁堡]]的[[病理学|病理學家]]J.H. Bennett發現有一群人死於脾臟腫大，他們的血液都有「顏色和質地」的變化，他用「白血球過多（leucocythemia）」來描述該病理狀況<ref>{{cite journal|author=Bennett JH| title=Two cases of hypertrophy of the spleen and liver, in which death took place from suppuration of blood |journal=Edinburgh Med Surg J| year=1845| volume=64| page=413}}</ref>。

白血病（leukemia）這個名詞是由[[魯道夫·菲爾紹|魯道夫·菲爾紹]]（Rudolf Ludwig Karl Virchow）——一位知名的德國病理學家——在1856年創造的。身為病理學界[[光学显微镜|光学显微镜]]的先驅，菲爾紹首度發現和Velpeau與Bennett的紀錄有相同症狀的患者血液中的白血球異常增多。由於菲爾紹並不知道白血球增多的病因，因此使用了leukemia（希臘文的白血球）這個字來描述此狀況<ref>{{cite book |last=Virchow |first=R |editor=Virchow R |title=Gesammelte Abhandlungen zur Wissenschaftlichen Medizin |chapter-url=https://archive.org/details/b21462161 |year=1856 |publisher=Meidinger |location=Frankfurt |language=de |chapter=Die Leukämie |page=[https://archive.org/details/b21462161/page/190 190]}}</ref>。

隨著新科技的進展，人們對急性骨髓性白血病的了解迅速增加。1877年，[[保罗·埃尔利希|保罗·埃尔利希]]（Paul Ehrlich）發展出了血液抹片[[染色_(生物學)|染色]]技術，使他得以描述不正常白血球的型態。{{tsl|en|Wilhelm Ebstein|Wilhelm Ebstein}}在1889年使用了「急性白血病」（acute leukemia）一詞，以區分進展迅速且致命的白血病和病程較緩和的{{tsl|en|chronic leukemia|慢性白血病}}<ref>{{cite journal|author=Ebstein W|title=Über die acute Leukämie und Pseudoleukämie|journal=Deutsch Arch Klin Med|year=1889|volume=44|pages=343}}</ref>。「骨髓性（myeloid）」這個詞彙則是由{{tsl|en|Franz Ernst Christian Neumann|Franz Ernst Christian Neumann}}在1869年創造的，他也是第一個發現白血球是由骨髓而非脾臟產生的病理學家，而骨髓的[[古希臘語|古希臘語]]正是μυєλός（''{{lang|grc-Latn|myelos}}''）。藉由[[骨髓檢查|骨髓檢查]]診斷白血病的方法則是由Mosler在1879提出<ref>{{cite journal|author=Mosler F|title=Klinische Symptome und Therapie der medullären Leukämie|journal=Berl Klin Wochenschr|year=1876|volume=13|pages=702}}</ref>。最後，{{tsl|en|Otto Naegeli|Otto Naegeli}}在1900年時發現了{{tsl|en|myeloblast|骨髓母細胞}}（即急性骨髓性白血病惡性細胞的來源），同時也將白血病區分為骨髓性和淋巴性兩個類型<ref>{{cite journal|author=Naegeli O|title=Über rothes Knochenmark und Myeloblasten|journal=Deutsche Medizinische Wochenschrift|year=1900|volume=26|pages=287–290|doi=10.1055/s-0029-1203820|issue=18|url=https://zenodo.org/record/1429862|access-date=2020-07-20|archive-date=2021-03-21|archive-url=https://web.archive.org/web/20210321150516/https://zenodo.org/record/1429862|dead-url=no}}</ref><ref>{{cite journal | author = Wang ZY | title = Ham-Wasserman Lecture: Treatment of Acute Leukemia by Inducing Differentiation and Apoptosis | journal = Hematology | volume = 2003 | issue = 1 | pages = 1–13 | year = 2003 | pmid = 14633774 | doi = 10.1182/asheducation-2003.1.1 }}</ref>。

2008年，急性骨髓性白血病成為第一種被完成全基因體[[DNA測序|定序]]的癌症，科學家將白血病細胞萃取豬的DNA拿來和正常的皮膚細胞比較，發現白血病細胞在一些先前從未被注意到的基因中也有突變<ref>{{cite journal |vauthors=Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, Dooling D, Dunford-Shore BH, McGrath S, Hickenbotham M, Cook L, Abbott R, Larson DE, Koboldt DC, Pohl C, Smith S, Hawkins A, Abbott S, Locke D, Hillier LW, Miner T, Fulton L, Magrini V, Wylie T, Glasscock J, Conyers J, Sander N, Shi X, Osborne JR, Minx P, Gordon D, Chinwalla A, Zhao Y, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson M, Baty J, Ivanovich J, Heath S, Shannon WD, Nagarajan R, Walter MJ, Link DC, Graubert TA, DiPersio JF, Wilson RK | title = DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome | journal = [[自然_(期刊)|Nature]] | volume = 456 | issue = 7218 | pages = 66–72 | year = 2008 | pmid = 18987736 | pmc = 2603574 | doi = 10.1038/nature07485 |bibcode = 2008Natur.456...66L }}</ref>。

==懷孕==
白血病很少在孕婦出現，孕婦的盛行率大約只有一萬分之一<ref name=Shapira />。孕婦的白血病該如何處理取決於白血病的類型，急性白血病通常需要迅速且積極的治療，儘管可能會有[[流產|流產]]和[[先天性障碍|胎兒畸形]]的風險，尤其在妊娠第一個三月期的發育特別敏感，進行化療將會有更高的風險<ref name=Shapira>{{cite journal |vauthors=Shapira T, Pereg D, Lishner M | title = How I treat acute and chronic leukemia in pregnancy | journal = Blood Rev. | volume = 22 | issue = 5 | pages = 247–59 | date = September 2008 | pmid = 18472198 | doi = 10.1016/j.blre.2008.03.006 }}</ref>。

==參考資料==
{{Reflist|2}}

== 外部連結 ==
{{Medical resources
|  ICD10 = {{ICD10|C|92|0|c|81}}  
|  ICD9 = {{ICD9|205.0}}  
|  ICDO = {{ICDO|9861|3}}  
|  OMIM = 602439  
|  MedlinePlus = 000542  
|  eMedicineSubj = med  
|  eMedicineTopic = 34  
|  DiseasesDB = 203  
|  MeshID = D015470  
}}{{Clear}}
* {{Curlie|Health/Conditions_and_Diseases/Cancer/Hematologic/Leukemia/Acute_Myelogenous/}}
* [https://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=cebpa-aml GeneReviews/NIH/NCBI/UW entry on Familial Acute Myeloid Leukemia (AML) with Mutated CEBPA] {{Wayback|url=https://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=cebpa-aml |date=20210827204536 }}
* [https://www.cancer.gov/types/leukemia/hp/child-aml-treatment-pdq PDQ statement on AML for health professionals] {{Wayback|url=https://www.cancer.gov/types/leukemia/hp/child-aml-treatment-pdq |date=20210321150517 }} at [[国家癌症研究所|National Cancer Institute]]

{{Myeloid malignancy}}

{{DEFAULTSORT:Acute Myeloid Leukemia}}
[[Category:急性白血病|Category:急性白血病]]
[[Category:RTT|Category:RTT]]